Patient Controlled Injectors Market Scope And Analysis

  • Report Code : TIPRE00015234
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Patient Controlled Injectors Market Analysis Report 2023 to 2031

Buy Now


Patient Controlled Injectors Market Report Scope

Report Attribute Details
Market size in 2021 US$ 3.71 Billion
Market Size by 2031 US$ 12.33 Billion
Global CAGR (2023 - 2031) 12.9%
Historical Data 2021-2022
Forecast period 2023-2031
Segments Covered By Product
  • Electronic Wearable Injectors
  • Mechanical Wearable Injectors
  • Infusion Pumps
By Application
  • Cancer Treatment
  • Auto-immune Treatment
  • Blood Disorders Treatment
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Gerresheimer AG
  • Johnson and Johnson Services Inc
  • Ypsomed AG
  • Westbourne Medical Limited
  • Enable Injections
  • scPharmaceuticals Inc
  • United Therapeutics Corporation
  • BD
  • West Pharmaceutical Services Inc
  • Owen Mumford Pharmaceutical Services
  • Patient Controlled Injectors Market News and Recent Developments

    The Patient Controlled Injectors Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for Patient Controlled Injectors Market:

    • Ypsomed (SIX: YPSN) has developed a new autoinjector platform for liquid medications with volumes ranging from 1.5 to 5.5 ml. The YpsoMate 5.5 is the latest addition to the growing YpsoMate family of devices and is based on the established technology of the YpsoMate 2.25 Pro. YpsoMate 5.5 enables the self-administration of larger volume medications for treating cancer, rare and autoimmune diseases. (Source: Ypsomed AG, Press Release, 2022)
    • Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector. (Source: Gerresheimer AG, Press Release, 2021)

    Patient Controlled Injectors Market Report Coverage and Deliverables

    The “Patient Controlled Injectors Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Market dynamics such as drivers, restraints, and key opportunities
    • Key future trends
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
    • Detailed company profiles